Meningococcal Polysaccharide Conjugate Vaccine Serogroups A, C, W-135 And Y (Menacwy-Tt)
Recommended · restricted VaccinesRestrictedNot applicable line
Prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W-135 and Y in adolescents aged 14-16 years (Year 10 students) and via a catch-up program for adolescents aged up to 19 years.
1
Submissions
2018–18
On the record
Redacted
ICER range
commercial-in-confidence
Redacted
Cost basis
Access path
- Mar 2018Recommended · restricted
vs no vaccine
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
The PBAC noted that cost-effectiveness could be brought into an acceptable range contingent upon a reduced price; specific ICER values are not stated in the public text.
The PBAC's recommendation was based on, among other matters, its assessment that the cost effectiveness of the MenACWY-TT vaccine could be brought into an acceptable range contingent upon a reduced price. PBAC · 2018
Decision context
PopulationAdolescents in Year 10 (15-16 years of age) who are meningococcal vaccine naïve, with a proposed catch-up program for adolescents/young adults aged up to 19 years of age.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2018 | Recommended · restricted | no vaccine | — | Single-arm |